Phase I evaluation of erlotinib and docetaxel with concomitant boost radiation for locoregionally advanced squamous cell carcinoma of the head and neck
Phase of Trial: Phase I
Latest Information Update: 25 Nov 2014
At a glance
- Drugs Docetaxel (Primary) ; Erlotinib (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- 06 Apr 2011 Planned End Date changed from 1 Dec 2010 to 1 Oct 2012, according to the ClinicalTrials.gov record.
- 02 Feb 2010 Planned end date changed from 1 Apr 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 09 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov